GraniteShares YieldBOOST Biotech ETF (BIOY) price, chart and fund profile
Price chart
Fund profile
BIOY's primary investment objective is to achieve 3 times (300%) the income generated from selling options on S&P Biotechnology Select Industry Index.
- Issuer
- GraniteShares Advisors LLC
- Industry
- Healthcare
- Inception
- May 5, 2026
- Assets under management
- $835,515.00
- Expense ratio
- 1.07%
- Net asset value
- $20.89
- NAV as of
- Aug 28, 2026
- Leverage
- 3×
- Fund page
- graniteshares.com↗
Frequently asked questions
What is GraniteShares YieldBOOST Biotech ETF (BIOY)?
BIOY's primary investment objective is to achieve 3 times (300%) the income generated from selling options on S&P Biotechnology Select Industry Index.
What is BIOY's expense ratio?
GraniteShares YieldBOOST Biotech ETF charges an annual expense ratio of 1.07%. The fund is issued by GraniteShares Advisors LLC.
How large is BIOY?
GraniteShares YieldBOOST Biotech ETF manages $835,515.00 in assets and has traded since May 5, 2026.
How do I buy shares of GraniteShares YieldBOOST Biotech ETF (BIOY)?
BIOY trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.